AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
4min chapter
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
VJHemOnc Podcast
Intro
Experts explore the latest updates in the treatment of chronic lymphocytic leukemia (CLL) and Richters transformation, including combinations of BTK and BCL2 inhibitors in first-line and relapse refractory settings from trials such as Sequoia and Nubrutinib with Sirotoclax. Promising combinations like xanabarutinib with Serontoclax are discussed, along with future randomized clinical trials comparing various therapies.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode